Oropouche virus disease outbreak

An outbreak of Oropouche virus disease is ongoing. Monitor the news and outbreak sections on this page for updates.

General Information

The information on these pages should be used to research health risks and to inform the pre-travel consultation.

Due to COVID-19, travel advice is subject to rapid change. Countries may change entry requirements and close their borders at very short notice. Travellers must ensure they check current Foreign, Commonwealth & Development Office (FCDO) travel advice in addition to the FCDO specific country page (where available) which provides additional information on travel restrictions and entry requirements in addition to safety and security advice.

Travellers should ideally arrange an appointment with their health professional at least four to six weeks before travel. However, even if time is short, an appointment is still worthwhile. This appointment provides an opportunity to assess health risks taking into account a number of factors including destination, medical history, and planned activities. For those with pre-existing health problems, an earlier appointment is recommended.

All travellers should ensure they have adequate travel health insurance.

A list of useful resources including advice on how to reduce the risk of certain health problems is available below.

Resources

Oropouche virus disease outbreak

An outbreak of Oropouche virus disease is ongoing. Monitor the news and outbreak sections on this page for updates.

Vaccine Recommendations

Details of vaccination recommendations and requirements are provided below.

All travellers

Travellers should be up to date with routine vaccination courses and boosters as recommended in the UK. These vaccinations include for example measles-mumps-rubella (MMR) vaccine and diphtheria-tetanus-polio vaccine.

Country-specific diphtheria recommendations are not provided here. Diphtheria tetanus and polio are combined in a single vaccine in the UK. Therefore, when a tetanus booster is recommended for travellers, diphtheria vaccine is also given. Should there be an outbreak of diphtheria in a country, diphtheria vaccination guidance will be provided.

Those who may be at increased risk of an infectious disease due to their work, lifestyle choice, or certain underlying health problems should be up to date with additional recommended vaccines. See the individual chapters of the 'Green Book' Immunisation against infectious disease for further details.

Certificate requirements

  • There are no certificate requirements under International Health Regulations.
  • There is a risk of yellow fever transmission in parts of Peru (see ‘Some Travellers’ section below).

Most travellers

The vaccines in this section are recommended for most travellers visiting this country. Information on these vaccines can be found by clicking on the blue arrow. Vaccines are listed alphabetically.

Hepatitis A is a viral infection transmitted through contaminated food and water or by direct contact with an infectious person. Symptoms are often mild or absent in young children, but the disease can be more serious with advancing age. Recovery can vary from weeks to months. Following hepatitis A infection immunity is lifelong.

Prevention

All travellers should take care with personal, food and water hygiene.

Hepatitis A vaccination

As hepatitis A vaccine is well tolerated and affords long-lasting protection, it is recommended for all previously unvaccinated travellers.

Hepatitis A in brief

Tetanus is caused by a toxin released from Clostridium tetani bacteria and occurs worldwide. Tetanus bacteria are present in soil and manure and may be introduced through open wounds such as a puncture wound, burn or scratch.

Prevention

Travellers should thoroughly clean all wounds and seek medical attention for injuries such as animal bites/scratches, burns or wounds contaminated with soil.

Tetanus vaccination

  • Travellers should have completed a tetanus vaccination course according to the UK schedule.
  • If travelling to a country or area where medical facilities may be limited, a booster dose of a tetanus-containing vaccine is recommended if the last dose was more than ten years ago even if five doses of vaccine have been given previously.

Country-specific information on medical facilities may be found in the 'health' section of the FCDO foreign travel advice pages.

Tetanus in brief

Typhoid is a bacterial infection transmitted through contaminated food and water. Previous typhoid illness may only partially protect against re-infection.

Vaccination is recommended for most travellers, particularly travellers visiting friends and relatives, those in contact with an infected person, young children, frequent or long-stay travellers visiting areas where sanitation and food hygiene are likely to be poor, and laboratory personnel who may handle the bacteria for their work.

Prevention

All travellers should take care with personal, food and water hygiene.

Typhoid vaccination

  • Oral and injectable typhoid vaccinations are available.
Typhoid in brief

Some travellers

The vaccines in this section are recommended for some travellers visiting this country. Information on when these vaccines should be considered can be found by clicking on the arrow. Vaccines are listed alphabetically.

Rabies is a viral infection which is usually transmitted following contact with the saliva of an infected animal most often via a bite, scratch or lick to an open wound or mucous membrane (such as on the eye, nose or mouth). Although many different animals can transmit the virus, most cases follow a bite or scratch from an infected dog. In some parts of the world, bats are an important source of infection.

Rabies symptoms can take some time to develop, but when they do, the condition is almost always fatal.

The risk of exposure is increased by certain activities and length of stay (see below). Children are at increased risk as they are less likely to avoid contact with animals and to report a bite, scratch or lick.

Rabies in Peru

Rabies is considered a risk and has been reported in domestic animals in this country. Bats may also carry rabies-like viruses.

Prevention

  • Travellers should avoid contact with all animals. Rabies is preventable with prompt post-exposure treatment.
  • Following a possible exposure, wounds should be thoroughly cleansed and an urgent local medical assessment sought, even if the wound appears trivial.
  • Post-exposure treatment and advice should be in accordance with national guidelines.

Rabies vaccination

A full course of pre-exposure vaccines simplifies and shortens the course of post-exposure treatment and removes the need for rabies immunoglobulin which is in short supply world-wide.

Pre-exposure vaccinations are recommended for travellers whose activities put them at increased risk including:

  • those at risk due to their work (e.g. laboratory staff working with the virus, those working with animals or health workers who may be caring for infected patients).
  • those travelling to areas where access to post-exposure treatment and medical care is limited.
  • those planning higher risk activities such as running or cycling.
  • long-stay travellers (more than one month).
Rabies in brief

TB is a bacterial infection most commonly affecting the lungs but can affect any part of the body. When a person with TB in their lungs or throat coughs or sneezes they could pass TB on to other people. TB is curable but can be serious if not treated.

The BCG vaccination helps to protect some people, particularly babies and young children who are at increased risk from TB.

Tuberculosis in Peru

This country has reported an annual TB incidence of greater than or equal to 40 cases per 100,000 population at least once in the last five years (further details).

Prevention

Travellers should avoid close contact with individuals known to have infectious pulmonary (lung) or laryngeal (throat) TB.

Those at risk during their work (such as healthcare workers) should take appropriate infection control and prevention precautions.

Tuberculosis (BCG) vaccination

BCG vaccine is recommended for those at increased risk of developing severe disease and/or of exposure to TB infection. See UK Health Security Agency Immunisation against infectious disease, the 'Green Book'.

For travellers, BCG vaccine is recommended for:

  • Unvaccinated, children under 16 years of age, who are going to live for more than 3 months in this country. A tuberculin skin test is required prior to vaccination for all children from 6 years of age and may be recommended for some younger children.
  • Unvaccinated, tuberculin skin test-negative individuals at risk due to their work such as healthcare or laboratory workers who have direct contact with TB patients or potentially infectious clinical material and vets and abattoir workers who handle animal material, which could be infected with TB.

There are specific contraindications to BCG vaccine. Health professionals must be trained and assessed as competent to administer this vaccine intradermally.

Following administration, no further vaccines should be administered in the same limb for 3 months.

The BCG vaccine is given once only, booster doses are not recommended.

Tuberculosis in brief

Yellow fever is a viral infection transmitted by mosquitoes which predominantly feed between dawn and dusk, but may also bite at night, especially in the jungle environment. Symptoms may be absent or mild, but in severe cases it can cause internal bleeding, organ failure and death.

Yellow fever in Peru

There is a risk of yellow fever transmission in parts of this country (see below).

Prevention

Travellers should avoid mosquito bites at all times.

Yellow fever vaccination

  • Vaccination is recommended for those aged 9 months of age and older travelling to the following areas at altitudes below 2,300m: the regions of Amazonas, Cuzco (for Cuzco city, Machu Pichu and the Inca trail see below), Huánuco, Junín, Loreto, Madre de Dios, Pasco, Puno (for Puno city see below), San Martin, Ucayali and designated areas of the following regions: far-north-eastern Ancash; far-north of Apurimac; northern and north-eastern Ayacucho; northern and eastern Cajamarca; far northern Huancavelica; eastern La Libertad, and eastern Piura.
  • Vaccination is generally not recommended for travellers whose itineraries are limited to areas west of the Andes: regions of Labayeque and Tumbes and designated areas of south, west and central Cajamarca and western Piura.
  • People aged 60 years or older should not be given the vaccine for travel to these areas with low potential for exposure due to a higher risk of life-threatening side effects.
  • Vaccination could be considered for a small subset of travellers (aged 9 months to less than 60 years of age) to such areas who are at increased risk because of:
    • prolonged travel.
    • heavy exposure to mosquito bites.
    • inability to avoid insect bites.
  • Vaccination is not recommended for travellers whose itineraries are limited to the following areas: all areas above 2,300m altitude, areas west of the Andes not listed above, the cities of Cuzco, Puno and the capital city of Lima, Machu Picchu, and the Inca Trail.
  • See vaccine recommendation map below.

The yellow fever vaccine is not suitable for all travellers, there are specific undesirable effects associated with it. This vaccine is only available at registered yellow fever vaccination centres. Health professionals should carefully assess the risks and benefits of the vaccine, and seek specialist advice if necessary.

Yellow fever in brief

Yellow fever vaccine recommendation map for Peru

Yellow fever vaccine recommendation map for Peru

  • Click on map to open in a new window

Oropouche virus disease outbreak

An outbreak of Oropouche virus disease is ongoing. Monitor the news and outbreak sections on this page for updates.

Malaria

Malaria is a serious illness caused by infection of red blood cells with a parasite called Plasmodium. The disease is transmitted by mosquitoes which predominantly feed between dusk and dawn.

Symptoms usually begin with a fever (high temperature) of 38°C (100°F) or more. Other symptoms may include feeling cold and shivery, headache, nausea, vomiting and aching muscles. Symptoms may appear between eight days and one year after the infected mosquito bite.

Prompt diagnosis and treatment is required as people with malaria can deteriorate quickly. Those at higher risk of malaria, or of severe complications from malaria, include pregnant women, infants and young children, the elderly, travellers who do not have a functioning spleen and those visiting friends and relatives.

Prevention

Travellers should follow an ABCD guide to preventing malaria:

Awareness of the risk – Risk depends on the specific location, season of travel, length of stay, activities and type of accommodation.

Bite prevention – Travellers should take mosquito bite avoidance measures.

Chemoprophylaxis – Travellers should take antimalarials (malaria prevention tablets) if appropriate for the area (see below). No antimalarials are 100% effective but taking them in combination with mosquito bite avoidance measures will give substantial protection against malaria.

Diagnosis – Travellers who develop a fever of 38°C [100°F] or higher more than one week after being in a malaria risk area, or who develop any symptoms suggestive of malaria within a year of return should seek immediate medical care. Emergency standby treatment may be considered for those going to remote areas with limited access to medical attention.

Risk areas

  • There is a low risk of malaria in the Amazon basin of Peru along the border with Brazil, particularly in Loreto province and in the other rural areas of Peru below 2,000m including that part of the Amazon Basin which borders Bolivia: awareness of risk and bite avoidance recommended.
  • There is no risk in the city of Lima and the coastal region south of Chiclayo: bite avoidance recommended.

Special risk groups

In low risk areas, antimalarials may be considered in exceptional circumstances for travellers who are at higher risk of malaria (such as long term travellers visiting friends and relatives), or of severe complications from malaria (such as the elderly [over 70 years], the immunosuppressed, those with complex co-morbidities, pregnant women, infants and young children). The final decision whether or not to advise antimalarials rests with the travel health advisor and the traveller after individual risk assessment.

Travellers with an absent or poorly functioning spleen should be dissuaded from travel to any area with risk of malaria. Where travel is essential awareness, rigorous bite avoidance and antimalarials should be advised, even for the low risk areas.

For special risk groups, you may wish to seek specialist advice. For the low risk areas in this country atovaquone/proguanil OR doxycycline OR mefloquine would be suitable options.

Antimalarial recommendations map

  • Click on map to open in a new window

Resources

Oropouche virus disease outbreak

An outbreak of Oropouche virus disease is ongoing. Monitor the news and outbreak sections on this page for updates.

Other Risks

There are some risks that are relevant to all travellers regardless of destination. These may for example include road traffic and other accidents, diseases transmitted by insects or ticks, diseases transmitted by contaminated food and water, sexually transmitted infections, or health issues related to the heat or cold.

Some additional risks (which may be present in all or part of this country) are mentioned below and are presented alphabetically. Select risk to expand information.

There is a risk of altitude illness when travelling to destinations of 2,500 metres (8,200 feet) or higher. Important risk factors are the altitude gained, rate of ascent and sleeping altitude. Rapid ascent without a period of acclimatisation puts a traveller at higher risk.

There are three syndromes; acute mountain sickness (AMS), high-altitude cerebral oedema (HACE) and high-altitude pulmonary oedema (HAPE). HACE and HAPE require immediate descent and medical treatment.

Altitude illness in Peru

There is a point of elevation in this country higher than 2,500 metres. Some example places of interest: Machu Picchu 2,430m, Cusco 3,399m; Inca trail max ~4,200m; Pisac 2,972m; Cerro de Pasco 4,330m; La Rinconada 5,100m; Puno 3,827m

Prevention

  • Travellers should spend a few days at an altitude below 3,000m.
  • Where possible travellers should avoid travel from altitudes less than 1,200m to altitudes greater than 3,500m in a single day.
  • Ascent above 3,000m should be gradual. Travellers should avoid increasing sleeping elevation by more than 500m per day and ensure a rest day (at the same altitude) every three or four days.
  • Acetazolamide can be used to assist with acclimatisation, but should not replace gradual ascent.
  • Travellers who develop symptoms of AMS (headache, fatigue, loss of appetite, nausea and sleep disturbance) should avoid further ascent. In the absence of improvement or with progression of symptoms the first response should be to descend.
  • Development of HACE or HAPE symptoms requires immediate descent and emergency medical treatment.
Altitude illness in brief

Insect or tick bites can cause irritation and infections of the skin at the site of a bite. They can also spread certain diseases.

Diseases in South America

There is a risk of insect or tick-borne diseases in some areas of South America. This includes diseases such as American Trypanosomiasis (Chagas Disease), chikungunya, leishmaniasis and West Nile virus.

Prevention

  • All travellers should avoid insect and tick bites day and night.
  • There are no vaccinations (or medications) to prevent these diseases.

Further information about specific insect or tick-borne diseases for this country can be found, if appropriate on this page, in other sections of the country information pages and the insect and tick bite avoidance factsheet.

Dengue is a viral infection spread by mosquitoes which mainly feed during daytime hours. It causes a flu-like illness, which can occasionally develop into a more serious life-threatening illness. Severe dengue is rare in travellers.

The mosquitoes that spread dengue are more common in towns, cities and surrounding areas.

Dengue in Peru

There is a risk of dengue in this country.

Prevention

  • Travellers should avoid mosquito bites particularly during daytime hours.
  • A dengue vaccine is licensed in the UK for the prevention of dengue disease in individuals from 4 years of age. The Joint Committee on Vaccination and Immunisation (JCVI) and World Health Organization are in the process of reviewing the product information. Recommendations on the use of this vaccine will be published in due course.
Dengue in brief

Seasonal influenza is a viral infection of the respiratory tract and spreads easily from person to person via respiratory droplets when coughing and sneezing. Symptoms appear rapidly and include fever, muscle aches, headache, malaise (feeling unwell), cough, sore throat and a runny nose. In healthy individuals, symptoms improve without treatment within two to seven days. Severe illness is more common in those aged 65 years or over, those under 2 years of age, or those who have underlying medical conditions that increase their risk for complications of influenza.

Seasonal influenza in Peru

Seasonal influenza occurs throughout the world. In the northern hemisphere (including the UK), most influenza occurs from as early as October through to March. In the southern hemisphere, influenza mostly occurs between April and September. In the tropics, influenza can occur throughout the year.

Prevention

All travellers should:

  • Avoid close contact with symptomatic individuals
  • Avoid crowded conditions where possible
  • Wash their hands frequently
  • Practise ‘cough hygiene’: sneezing or coughing into a tissue and promptly discarding it safely, and washing their hands
  • Avoid travel if unwell with influenza-like symptoms
  • A vaccine is available in certain circumstances (see below)*
*In the UK, seasonal influenza vaccine is offered routinely each year to those at higher risk of developing of severe disease following influenza infection, and certain additional groups such as healthcare workers and children as part of the UK national schedule (see information on vaccination). For those who do not fall into these groups, vaccination may be available privately.

If individuals at higher risk of severe disease following influenza infection are travelling to a country when influenza is likely to be circulating they should ensure they received a flu vaccination in the previous 12 months.

The vaccine used in the UK protects against the strains predicted to occur during the winter months of the northern hemisphere. It is not possible to obtain vaccine for the southern hemisphere in the UK, but the vaccine used during the UK influenza season should still provide important protection against strains likely to occur during the southern hemisphere influenza season, and in the tropics.

Avian influenza

Avian influenza viruses can rarely infect and cause disease in humans. Such cases are usually associated with close exposure to infected bird or animal populations. Where appropriate, information on these will be available in the outbreaks and news sections of the relevant country pages. Seasonal influenza vaccines will not provide protection against avian influenza.

Avian influenza in brief

Poor air quality is a significant public health problem in many parts of the world. Exposure to high levels of air pollution over short time periods (e.g. minutes/hours/days) and longer time periods (e.g. years) is linked to many different acute and chronic health problems. These effects are mainly on the respiratory (lungs and airways) and cardiovascular (heart function and blood circulation) systems.

Current information on world air quality is available from the world air quality index project.

Prevention

Travellers with health problems that might make them more vulnerable to the effects of air pollution who are travelling to areas of high pollution should:

  • discuss their travel plans with their doctor, and carry adequate supplies of their regular medication.
  • take sensible precautions to minimise their exposure to high levels of air pollution.
  • check local air quality data and amend their activities accordingly.
  • take notice of any health advisories published by the local Ministry of Health and Department for Environment, and follow the guidance provided.

It is unclear if face masks are beneficial at reducing exposure and may make breathing more difficult for those with pre-existing lung conditions. Those who choose to use one should make sure that the mask fits well and know how to wear it properly.

Outdoor air quality in brief

Zika virus (ZIKV) is a viral infection spread by mosquitoes which predominantly feed during daytime hours. A small number of cases of sexual transmission of ZIKV have also been reported. Most people infected with ZIKV have no symptoms. When symptoms do occur, they are usually mild and short-lived. Serious complications and deaths are not common. However, ZIKV is a cause of Congenital Zika Syndrome (microcephaly and other congenital anomalies) and neurological complications such as Guillain-Barré syndrome.

Zika virus in Peru

There is a risk of Zika virus in this country. Details of specific affected areas within this country are not available, but information on current outbreaks where available will be reported on our outbreak surveillance database.

Pregnant women should discuss the suitability of travel and the potential risk that Zika virus may present with their health care provider.

Prevention

  • All travellers should avoid mosquito bites particularly during daytime hours.
  • There is no vaccination or medication to prevent Zika virus infection.
  • Women should avoid becoming pregnant while travelling in this country, and for 2 months (8 weeks) after their last possible Zika virus exposure* (see below if male partner has travelled).
  • If a woman develops symptoms compatible with Zika virus infection, it is recommended she avoids becoming pregnant for a further 2 months following recovery.
  • Women who visited this country while pregnant, or who become pregnant within 2 months after their last possible Zika virus exposure*, should contact their GP, obstetrician or midwife for further advice, even if they have not been unwell.

Please note screening of returning travellers without Zika virus symptoms is not available on the NHS. Couples planning pregnancy in the very near future should consider whether they should avoid travel to a country or area with risk of Zika virus, rather than delay conception for the recommended period (see below) after travel. This particularly includes couples in assisted fertility programmes.

Prevention of sexual transmission

Couples should follow guidance on prevention of sexual transmission of Zika virus and avoid conception as follows:

  • If both partners travelled, for 3 months after last possible Zika virus exposure.*
  • Male traveller only, for 3 months after last possible Zika virus exposure.*
  • Female traveller only, for 2 months after last possible Zika virus exposure.*

See further information for pregnant women, their partners and couples planning pregnancy.

*Last possible Zika virus exposure is defined as the later of either the date of leaving a country or area with risk for Zika virus transmission, or the date on which unprotected sexual contact with a potentially infectious partner took place.

See detailed guidance on factors to consider when assessing the risk of Zika virus.

Zika virus in brief

Oropouche virus disease outbreak

An outbreak of Oropouche virus disease is ongoing. Monitor the news and outbreak sections on this page for updates.

COVID-19

COVID-19 disease is caused by the coronavirus SARS-CoV2. The main symptoms of COVID-19 are a new continuous cough, a high temperature, and a loss of, or change in, normal sense of taste or smell. Symptoms range from mild to life-threatening. Older people and those with underlying health problems are more likely to develop severe disease.

COVID-19 is spread through close contact with people who have the virus. It is mainly transmitted from person to person by breathing in droplets produced when someone infected with the virus breathes, speaks, coughs or sneezes. It is also spread by touching the infected droplets on surfaces, then touching the eyes, nose or mouth.

COVID-19 vaccines provide high levels of protection against severe illness, hospitalisation, or dying from the virus. Vaccination against COVID-19 reduces, but does not eliminate the risk of infection, so social distancing and personal and respiratory hygiene remain important interventions, particularly during overseas travel.

Travellers should always check the UK Foreign, Commonwealth & Development Office (FCDO) travel advice and their country-specific pages for the latest COVID-19 travel advisories which may include information on travel restrictions, quarantine, COVID-19 testing or vaccination requirements. This includes considering the recommendations and requirements for any transit countries.

Travellers should be aware that COVID-19 case numbers in individual countries/areas can increase rapidly, and healthcare capacity and country requirements can change at short notice.

COVID-19 in Peru

Most countries worldwide present a risk of exposure to COVID-19. The risk of COVID-19, public health policy, and travel advice or restrictions may change quickly, therefore travellers should ensure they have access to up to date information on COVID-19 and be prepared for rapid changes in guidance both before and during travel.

All travellers should check the FCDO travel advice and carefully consider their personal situation and risks of COVID-19 before travel to this country. This is particularly important in those at higher risk from COVID-19 who may wish to seek medical advice before travel.

Individuals entering or returning to the UK may be required to follow additional UK border measures.

Prevention

If travelling to this country, travellers should:

  • Consider the risk at all destinations including any transit countries, and the risk during travel itself.
  • Check with the airline/tour operator about preventive measures in place to reduce risk during travel.
  • Follow the latest guidance on social distancing and face coverings, including any local requirements and maintain good hand, respiratory, and personal hygiene at all times. This may be particularly important if staying with friends and family.
  • Ensure they are up to date with their COVID-19 vaccination courses and boosters as recommended in the UK vaccination programme.

See guidance on factors to consider when assessing the risk of COVID-19 for travellers.

If travellers develop COVID-19 symptoms while abroad, they should:

  • Follow local guidelines on self-isolation, testing and avoiding travel.
  • Contact their travel insurance provider.
  • Seek medical advice if needed.
COVID-19 in brief

Oropouche virus disease outbreak

An outbreak of Oropouche virus disease is ongoing. Monitor the news and outbreak sections on this page for updates.

Oropouche virus disease outbreak

An outbreak of Oropouche virus disease is ongoing. Monitor the news and outbreak sections on this page for updates.

News

Oropouche virus disease: information for travellers and health professionals

Information on risks and prevention measures for travellers and health professionals

Updated: 21 November 2024
Take extra precautions

Changes to the Country Information pages: Hepatitis B

NaTHNaC has reviewed and updated country-specific Hepatitis B information and vaccine recommendations

Updated: 11 July 2024
Take usual precautions

Yellow fever update

Yellow fever cases continue to be reported in Africa and South America

Updated: 04 April 2024
Take usual precautions

Changes to the Country Information pages: Zika

NaTHNaC has reviewed and updated country-specific Zika information and prevention advice

Updated: 02 January 2024
Take extra precautions

Malaria: a reminder for travellers over the winter holiday season

Advice for travellers and health professionals about malaria

Updated: 21 December 2023
Take usual precautions

Oropouche virus disease outbreak

An outbreak of Oropouche virus disease is ongoing. Monitor the news and outbreak sections on this page for updates.

Outbreaks

Using information collated from a variety of sources, we regularly review and update information on overseas disease outbreaks and other health issues that may affect the UK traveller.

Please note that not all cases of disease or outbreaks are reported; some diseases may only be reported if they occur outside of the usual recognised risk area or season, or they have been reported in greater than usual numbers.

Further information on the Outbreak Surveillance section.

 


Yellow fever in Bolivia, Brazil, Colombia, Guyana, Peru

On 9 November 2024, the Pan American Health Organization reported 50 confirmed cases of yellow fever, including 24 deaths since the start of 2024. Cases have been reported in the Plurinational State of Bolivia (8 cases, including 4 deaths), Brazil (3 cases, including 2 deaths), Colombia (17 cases, including 9 deaths), Guyana (3 cases), and Peru (19 cases, including 9 deaths). Please see our Topics in Brief article for further details on yellow fever.

Take usual precautions

31 July 2024
Peru + Huánuco
Junín
Madre de Dios
San Martín
Ucayali

Yellow fever in Peru

As of 29 July 2024, a total of 16 confirmed yellow fever cases, including seven deaths, have been reported in 2024.

Take usual precautions

24 July 2024

Oropouche virus disease in Peru

As of 16 July 2024 a total of 287 confirmed cases of Oropouche virus disease have been reported since the start of the year. Brazil have recently reported two suspected cases of vertical transmission of the virus (spread of the virus from pregnant women to their baby). These cases are still under investigation.

Take usual precautions